Default factors for interspecies differences in the major routes of xenobiotic elimination

Human and Ecological Risk Assessment (HERA)

Volumn 7, Issue 1, 2001, Pages 181-201

  Walton, Kim ^a   Dorne, Jean Lou C M ^a   Renwick, Andrew G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Interspecies; Metabolism; Toxicokinetics; Uncertainty factors

Indexed keywords

EID: 23044527157     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/20018091094295     Document Type: Article

References (20)

1. Bauer LA, Brown T, Gibaldi M, et al. 1982. Influence of long-term infusions on lidocaine kinetics. Clin Pharmacol Ther 31:433-7
2. Benedek IH, Joshi AS, Pieniaszek HJ, et al. 1995. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35:1181-6
3. Bochner F, Williams DB, Morris PMA, et al. 1988 Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 35:287-94
4. Boyes RN, Adams HJ, and Duce BR. 1970. Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs. J Pharmacol Exp Ther 174:1-8
5. Brantmark B, Wahlin Boll E, and Melander A. 1982. Bioavailability of acetylsalicylic acid and salicylic acid from rapid- and slow-release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 22:309-14
6. Calabrese EJ, Beck BD, and Chappell WR. 1992. Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area? Regul Toxicol Pharmacol 15:172-9
7. de Boer AG, Breimer DD, and Mattie H. 1979. Rectal bioavailability of lidocaine in man: Partial avoidance of "first-pass" metabolism. Clin Pharmacol Ther 26:701-9
8. de Boer AG, Brcimer DD, Pronk J, et al. 1980. Rectal bioavailability of lidocaine in rats: Absence of significant first-pass elimination. J Pharm Sci 69:804-7
9. de Leede LGJ, de Boer AG, Roozen CPJM, et al. 1983. Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats. J Pharmacol Exp Ther 255:181-5
10. Dolphin CT, Caldwell J, and Smith RL. 1987. Effect of Interferon synthesis upon the metabolism of [carboxyl-(14)C]-aspirin in the mouse. Biochem Pharmacol 36:2437-42
11. Dorne J-LCM, Walton K, and Renwick AG. 2001a. Uncertainty factors for chemical risk assessment: Human variability in the pharmacokinetics of CYP1A2 probe substrates. In press. Food Chem. Toxicol.
12. Dorne J-LCM, Walton K and Renwick AG. 2001b. Uncertainty factors for chemical risk assessment: Human variability in glucuronidation. In preparation
13. Dourson ML and Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol 3:224-38
14. Dourson ML, Felter SP, and Robinson D. 1996. Evolution of science-based factors in noncancer risk assessment. Regul Toxicol Pharmacol 24:108-20
15. Favari L, Mourelle M, and Amezcua JL. 1987. Aspirin disposition in rats acutely intoxicated with CCl-4. J Appl Toxicol 7:361-5
16. Fu CJ, Mclethil S, and Mason WD. 1991. The pharmacokinetics of aspirin in rats and the effect of buffer. J Pharmacokinet Biopharm 19:157-73
17. Fuchshofen M, Zilly W, Epping J, et al 1978. [Pharmacokinetics of lidocaine after intravenous and oral administration in patients with liver cirrhosis] Pharmakokinetik von Lidokain nach intravenoser und oraler Applikation bei Patienten mit Lebercirrhose. Verh Dtsch Ges Inn Med 1110-2
18. Gaspari F, Perico N, Locatelli M, et al. 1989. Renal handling of aspirin in the rat. J Pharmacol Exp Ther 251:295-304
19. Gayawali K, Pandhi P, and Sharma PL. 1991. Determination of the optimal analgesia-potentiating dose of caffeine and a study of its effect on the pharmacokinetics of aspirin in mice. Methods Find Exp Clin Pharmacol 13:529-33
20. Goldberg MJ, Spector R, and Johnson GF. 1982. Racial background and lidocaine pharmacokinetics. J Clin Pharmacol 22:391-4